Propulsion of Atopic Dermatitis Clinical Trial Pipeline as Novel and Extensive 100+ Therapies Likely to Enter in the Domain | DelveInsight

DelveInsight's, "Atopic Dermatitis Pipeline Insight, 2023" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Atopic Dermatitis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Atopic Dermatitis clinical trials studies, Atopic Dermatitis NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key Takeaways from the Atopic Dermatitis Pipeline Report
• DelveInsight's Atopic Dermatitis Pipeline analysis depicts a robust space with 100+ active players working to develop 110+ pipeline treatment therapies.

• The leading Atopic Dermatitis Companies include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

• Promising Atopic Dermatitis pipeline therapies such as Baricitinib, Lebrikizumab, MEDI9929, and others.

• The Atopic Dermatitis Companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The Atopic Dermatitis pipeline therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

Request a sample and discover the recent breakthroughs happening in the Atopic Dermatitis Pipeline landscape @ Atopic Dermatitis Pipeline Outlook- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Atopic Dermatitis Overview
Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease.

Recent Developmental Activities in the Atopic Dermatitis Treatment Landscape
• In November 2022, Alphyn Biologics announced that it had completed the first cohort of its Phase IIa clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without bacterial infection, which is sometimes associated with the disease. Top-line results are expected in approximately eight weeks.

• In September 2022, selectION announced that it has begun dosing patients in a Phase Ib trial to evaluate safety and efficacy, including duration of clinical benefit, of si-544 in patients with mild to severe atopic dermatitis.

For further information, refer to the detailed Atopic Dermatitis Drugs Launch, Atopic Dermatitis Developmental Activities, and Atopic Dermatitis News, click here for Atopic Dermatitis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Atopic Dermatitis Emerging Drugs Profiles

Tapinarof: Dermavant Sciences
Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that binds and activates the aryl hydrocarbon receptor in multiple cell types, including cells of the target tissue-human skin. Tapinarof has also shown to moderate proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impact barrier gene expression in primary human keratinocytes. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Atopic dermatitis.

Etrasimod: Pfizer
Etrasimod is an oral, once daily, selective sphingosine-1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases and is in Phase II/III stage of development for the treatment of patients with Atopic dermatitis.

B244: AOBiome
AOBiome's B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Atopic dermatitis.

Lirentelimab: Allakos Inc.
Lirentelimab (AK002) is an afucosylated, humanized IgG1 monoclonal antibody which activates the inhibitory receptor Siglec-8. Additionally, Lirentelimab depletes eosinophils via antibody dependent cellular cytotoxicity (ADCC) in blood. Siglec-8 is a member of the family of cell surface receptors called Sialic acid-binding immunoglobulin-type lectins (Siglecs).

Allakos initiated a Phase II trial evaluating subcutaneous Lirentelimab versus placebo in patients with atopic dermatitis. Results from this trial are expected in the second half of 2023.

QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
QY201 acts on Jak1/Tyk2 dual targets with higher activity and selectivity, which is significantly superior to the similar drugs. QY201 is an innovative drug for the treatment of atopic dermatitis. QY201 was independently developed by E-nitiate with global patents, is undergoing Phase I/II clinical trial for atopic dermatitis.

Atopic Dermatitis Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.

Find out more about the Atopic Dermatitis Pipeline Segmentation, Therapeutics Assessment, and Atopic Dermatitis Emerging Drugs @ Atopic Dermatitis Treatment Landscape- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Atopic Dermatitis Pipeline Report

• Coverage- Global

• Atopic Dermatitis Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

• Atopic Dermatitis pipeline Therapies- Baricitinib, Lebrikizumab, MEDI9929, and others.

• Atopic Dermatitis Segmentation: Phases, Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Atopic Dermatitis Pipeline Companies and Therapies, click here @ Atopic Dermatitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Atopic Dermatitis Executive Summary
3. Atopic Dermatitis: Overview
4. Atopic Dermatitis Pipeline Therapeutics
5. Atopic Dermatitis Therapeutic Assessment
6. Atopic Dermatitis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Amlitelimab: Kymab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Atopic Dermatitis Key Companies
21. Atopic Dermatitis Key Products
22. Atopic Dermatitis- Unmet Needs
23. Atopic Dermatitis- Market Drivers and Barriers
24. Atopic Dermatitis- Future Perspectives and Conclusion
25. Atopic Dermatitis Analyst Views
26. Atopic Dermatitis Key Companies
27. Appendix

Got Queries? Find out the related information on Atopic Dermatitis Mergers and acquisitions, Atopic Dermatitis Licensing Activities @ Atopic Dermatitis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.